Search
for
Sort by
Research 121–150 of 1000+
- Deucravacitinib in dermatology: current indication and existing off-label data
- Follicular Vitiligo: A Rare and Under Recognized Variant
- AP-1 and TGFß cooperativity drives non-canonical Hedgehog signaling in resistant basal cell carcinoma
- Selective Janus kinase 1 inhibition resolves inflammation and restores hair growth offering a viable treatment option for alopecia areata
- The evolutionary impact of androgen levels on prostate cancer in a multi-scale mathematical model
- Upadacitinib for the Treatment of Systemic Immune Co-Morbidity in One Case: Alopecia Areata, Vitiligo, Ankylosing Spondylitis, and Allergic Rhinitis-Asthma – Multifaceted Control
- JAK-centric explainable few-shot gene-expression diagnosis framework for alopecia via MultiPLIER priors and relation-style set-to-set comparison
- In vitro selective inhibition of human UDP-glucuronosyltransferase (UGT) 1A4 by finasteride, and prediction of in vivo drug–drug interactions
- Androgenetische Alopezie beim Mann . Male androgenetic alopecia
- PERAN KELENJAR SEBASEA PADA ALOPESIA ANDROGENIK
- Tufted hair folliculitis in a woman treated with trastuzumab
- Moving Beyond Boundaries: Utilization of Longitudinal Exposure–Response Model for Bounded Outcome Score to Inform Decision Making in the Accelerated Drug Development Paradigm
- Unraveling Ritlecitinib: an in-depth analysis of JAK3 inhibitor for the treatment of alopecia areata
- 397 Predictive modeling of drug response and mechanism of action in alopecia areata clinical trials
- 724 - A phase 2b, randomized, double-blinded, parallel-group, placebo-controlled study to evaluate the efficacy and safety of rezpegaldesleukin in adults with severe to very-severe alopecia areata
- Preclinical Pharmacology, Antitumor Activity, and Development of Pharmacodynamic Markers for the Novel, Potent AKT Inhibitor CCT128930
- Emerging Topical and Systemic JAK Inhibitors in Dermatology
- Jak inhibitors in the treatment of alopecia areata - a literature review
- Epidemiology and treatment modalities for the management of benign prostatic hyperplasia
- Janus Kinase Inhibitors in Dermatology: Part 1 — General Considerations and Applications in Vitiligo and Alopecia Areata
- 5α-Reductase Inhibitors – The Finasteride Story
- Post-marketing safety signals of four JAK inhibitors for alopecia areata: an indication-restricted FAERS pharmacovigilance study
- Janus kinase inhibitors for alopecia areata: A narrative review
- JAK Inhibitor Therapy in Alopecia Areata with Latent Hepatitis B Virus or Tuberculosis Infection: A Safety Assessment
- Inhibidores de JAK: usos en dermatología. Parte 1: generalidades, aplicaciones en vitíligo y en alopecia areata
- Novel aldo-keto reductase 1C3 inhibitor affects androgen metabolism but not ovarian function in healthy women: a phase 1 study
- JAK Inhibitors in the Treatment of Alopecia Areata: Efficacy, Safety, and Long-term Outcomes
- When JAK inhibitors are off the table: durable remission of severe alopecia areata with dexamethasone oral mini-pulse and a focused review
- 62202 Network meta-analysis (NMA) of FDA-approved JAK inhibitors for alopecia areata (AA) with at least 50% hair loss per SALT score
- 013 IL-15/IL-15Rα signaling is a guardian of human hair follicle immune privilege and promotes hair growth